Filtered By:
Condition: Bleeding
Education: Academia
Procedure: Heart Valve Surgery

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 37 results found since Jan 2013.

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study
Conclusion The ADVANCE study demonstrates the safety and effectiveness of the CoreValve System with low mortality and stroke rates in higher risk real-world patients with severe aortic stenosis.
Source: European Heart Journal - October 7, 2014 Category: Cardiology Authors: Linke, A., Wenaweser, P., Gerckens, U., Tamburino, C., Bosmans, J., Bleiziffer, S., Blackman, D., Schafer, U., Muller, R., Sievert, H., Sondergaard, L., Klugmann, S., Hoffmann, R., Tchetche, D., Colombo, A., Legrand, V. M., Bedogni, F., lePrince, P., Schu Tags: TAVI Source Type: research

Results of surgical aortic valve replacement and transapical transcatheter aortic valve replacement in patients with previous coronary artery bypass grafting
CONCLUSIONS Reported differences in mortality and morbidity after TaTAVR and RAVR reflect differences in baseline risk profiles. Given the lower trend for renal complications, patients at higher perioperative renal risk might be better served by TaTAVR.
Source: Interactive CardioVascular and Thoracic Surgery - May 25, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Onorati, F., D'Onofrio, A., Biancari, F., Salizzoni, S., De Feo, M., Agrifoglio, M., Mariscalco, G., Lucchetti, V., Messina, A., Musumeci, F., Santarpino, G., Esposito, G., Santini, F., Magagna, P., Beghi, C., Aiello, M., Ratta, E. D., Savini, C., Troise, Tags: Molecular biology, Transplantation - heart, Basic research vascular Adult Cardiac Source Type: research

Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial
Conclusions This small trial showed that SAPT (vs. DAPT) tended to reduce the occurrence of major adverse events following TAVR. SAPT reduced the risk for major or life-threatening events while not increasing the risk for MI or stroke. Larger studies are needed to confirm these results. (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation: The ARTE Trial [ARTE], NCT01559298; Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI [ARTE], NCT02640794)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - July 3, 2017 Category: Cardiology Authors: Rodes-Cabau, J., Masson, J.-B., Welsh, R. C., Garcia del Blanco, B., Pelletier, M., Webb, J. G., Al-Qoofi, F., Genereux, P., Maluenda, G., Thoenes, M., Paradis, J.-M., Chamandi, C., Serra, V., Dumont, E., Cote, M. Tags: Structural Source Type: research

Transapical aortic valve replacement in extreme-risk patients: outcome, risk factors and mid-term results ADULT CARDIAC
CONCLUSIONS TA-TAVR in extreme-risk patients carries a moderate risk of hospital mortality. Severe comorbidities and presence of residual paravalvular leakages affect the mid-term survival, whereas surviving patients have an acceptable quality of life without rehospitalizations for cardiac decompensation.
Source: European Journal of Cardio-Thoracic Surgery - April 8, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Ferrari, E., Namasivayam, J., Marcucci, C., Gronchi, F., Berdajs, D., Niclauss, L., von Segesser, L. K. Tags: ADULT CARDIAC Source Type: research

Transapical Aortic Valve Implantation—An Australian Experience
Conclusion: Good short-term outcomes and low or zero mortality are achievable with transapical TAVI at an Australian institution.
Source: Heart, Lung and Circulation - December 6, 2013 Category: Cardiology Authors: Michael Seco, Gonzalo Martinez, Paul G. Bannon, Bruce L. Cartwright, Mark Adams, Martin Ng, Michael K. Wilson, Michael P. Vallely Tags: Original Articles Source Type: research

Revisiting Sex Equality With Transcatheter Aortic Valve Replacement Outcomes A Collaborative, Patient-Level Meta-Analysis of 11,310 Patients
BackgroundThere has been conflicting clinical evidence as to the influence of female sex on outcomes after transcatheter aortic valve replacement.ObjectivesThe aim of this study was to evaluate the impact of sex on early and late mortality and safety end points after transcatheter aortic valve replacement using a collaborative meta-analysis of patient-level data.MethodsFrom the MEDLINE, Embase, and the Cochrane Library databases, data were obtained from 5 studies, and a database containing individual patient-level time-to-event data was generated from the registry of each selected study. The primary outcome of interest was...
Source: Journal of the American College of Cardiology - July 13, 2015 Category: Cardiology Source Type: research

Impact of pre ‐existing or new‐onset atrial fibrillation on 30‐day clinical outcomes following Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: Prior or new‐onset AF within 30 days of transfemoral TAVR is noted in more than one‐third of patients. Despite greater baseline comorbidities than non‐AF patients, AF was not associated with greater risk of adjusted 30‐day outcomes. In the BRAVO 3 trial, early outcomes were similar regardless of anticoagulant strategy in each group. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - May 1, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Christian Hengstenberg, Jaya Chandrasekhar, Samantha Sartori, Thierry Lefevre, Ghada Mikhail, Nicolas Meneveau, Christophe Tron, Raban Jeger, Christian Kupatt, Birgit Vogel, Serdar Farhan, Sabato Sorrentino, Madhav Sharma, Clayton Snyder, Oliver Husser, P Tags: VSD ‐ Valvular and Structural Heart Diseases Source Type: research

Impact of Antithrombotic Regimen on Mortality, Ischemic, and Bleeding Outcomes after Transcatheter Aortic Valve Replacement
ConclusionsThe risk of the composite outcome of death, MI, stroke, or major bleeding at 2-year follow-up was significantly higher in TAVR patients treated with TT or SAC versus AP, even after multivariate adjustment.
Source: Cardiology and Therapy - May 19, 2018 Category: Cardiology Source Type: research

Postoperative warfarin following mitral valve repair or bioprosthetic valve replacement.
CONCLUSION: The use of postoperative warfarin following MVR does not reduce the incidence of stroke at early follow up. However, there remains a trend for improved long-term outcomes in those patients receiving postoperative warfarin therapy. PMID: 24383387 [PubMed - indexed for MEDLINE]
Source: Journal of Heart Valve Disease - December 1, 2014 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Complications and Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement With Edwards SAPIEN & SAPIEN XT Valves: A Meta‐Analysis of World‐Wide Studies and Registries Comparing the Transapical and Transfemoral Accesses
ConclusionThis meta‐analysis demonstrates a decreased 30‐day and 1‐year mortality in TF TAVR as compared to TA TAVR. Post‐procedure acute kidney injury and the need for renal replacement therapy are also significantly lower in the TF group. These differences hold true even after utilizing the standardized Valve Academic Research Consortium criteria.
Source: Journal of Interventional Cardiology - May 20, 2015 Category: Cardiology Authors: Abhijit Ghatak, Chirag Bavishi, Rhanderson N. Cardoso, Conrad Macon, Vikas Singh, Apurva O. Badheka, Santosh Padala, Mauricio G. Cohen, Raul Mitrani, William O'Neill, Eduardo De Marchena Tags: Original Investigation Source Type: research

Thirty-Day Outcomes in 100 Consecutive Patients Undergoing Transfemoral Aortic Valve Replacement With the Portico Valve on an All-Comer Basis.
CONCLUSIONS: Our immediate and 30-day post-TAVR results support favorable survival comparable to other studies, and significant clinical improvement with the Portico valve in non-selected patients in a real-world setting, with short-term complications being uncommon. PMID: 29207365 [PubMed - in process]
Source: The Journal of Invasive Cardiology - December 6, 2017 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Treatment of Aortic Stenosis With a Self-Expanding, Resheathable Transcatheter Valve: One-Year Results of the International Multicenter Portico Transcatheter Aortic Valve Implantation System Study Structural Heart Disease
Conclusions— The Portico TAVI system is safe and effective at 1 year, yielding low mortality and stroke rates in high-risk patients with severe AS. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique identifier: NCT01493284.
Source: Circulation: Cardiovascular Interventions - February 14, 2018 Category: Cardiology Authors: Linke, A., Holzhey, D., Mollmann, H., Manoharan, G., Schafer, U., Frerker, C., Worthley, S. G., van Boven, A. J., Redwood, S., Kovac, J., Butter, C., Sondergaard, L., Lauten, A., Schymik, G., Walther, T. Tags: Aortic Valve Replacement/Transcatheter Aortic Valve Implantation Structural Heart Disease Source Type: research

Oral anti-Xa anticoagulation after Trans-Aortic Valve Implantation for Aortic Stenosis: The randomized ATLANTIS trial
Conclusions ATLANTIS tests the superiority of an apixaban-based strategy versus the recommended standard of care strategy to reduce the risk of post-TAVR thromboembolic and bleeding complications in an all comer population.
Source: American Heart Journal - March 10, 2018 Category: Cardiology Source Type: research